A team of multiple myeloma experts review a patient profile, offering preliminary insights and underscoring the importance of advanced practice providers in optimizing patient care.
Insights on Evolving Treatment Strategies for Multiple Myeloma
The panel provides key takeaways on the most impactful innovations shaping the future of multiple myeloma treatment.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
Lower Basal Inflammation, Tumor Burden Linked to PFS Improvements With Ide-Cel in Myeloma
Patients with relapsed/refractory multiple myeloma who also had a lower tumor burden were more likely to derive deeper responses to idecabtagene vicleucel.
Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape
Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.
Belantamab Mafodotin Combo Extends PFS vs Daratumumab in Multiple Myeloma
These data may support belantamab mafodotin, bortezomib, and dexamethasone as a new standard of care for patients with relapsed/refractory multiple myeloma.
Teclistamab Regimen Provides Early Responses, Manageable Safety in Multiple Myeloma
Findings from this safety run-in cohort of teclistamab, daratumumab, and lenalidomide in newly diagnosed multiple myeloma will steer how randomization of the MajesTEC-7 trial will commence.
Luspatercept Improves Response Rates, Transfusion Independence for Lower-Risk MDS
Long-Term Data Support Teclistamab in Relapsed, Refractory Myeloma
Outpatient CAR T-Cell Therapy May Be Safe, Feasible for Relapsed/Refractory Non-Hodgkin Lymphoma
ASCO Offers an ‘Eye-Opening Experience’ for Nurse Practitioners